



SuperGen Announces Achievement of \$20 Million Dacogen(TM) (decitabine) Injection Milestone

DUBLIN, Calif., May 26 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that the first commercial shipment of Dacogen™ (decitabine) injection was released by MGI PHARMA, INC. to wholesale drug distributors earlier this week. Under the terms of its exclusive worldwide licensing agreement with MGI PHARMA, SuperGen has achieved the \$20 million commercialization milestone. Additionally, SuperGen will earn a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin™ (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent® (pentostatin for injection), Mitomycin, and Surface Safe® cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit <http://www.supergen.com>.

Contacts:

SuperGen

Timothy L. Enns

S.V.P., Corporate Communications
& Business Development

Tel: (925) 560-0100 x111

E-mail: tenns@supergen.com

Noonan Russo

Sharon Weinstein

Director of Investor Relations

Tel: (212) 845-4271

E-mail: sharon.weinstein@eurorscg.com

SOURCE SuperGen, Inc.

05/26/2006

CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & Business Development of SuperGen, +1-925-560-0100 ext. 111, tenns@supergen.com; or Sharon Weinstein, Director of Investor Relations of Noonan Russo, +1-212-845-4271, sharon.weinstein@eurorscg.com
Web site: <http://www.supergen.com>
(SUPG)